Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | OXTR | P30559 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167355 | 0.89 | ALDH1A1 (0.59) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL6181487 | 0.87 | ALDH1A1 (0.56) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL1356015 | 0.87 | ALDH1A1 (0.79) | MAPTSMN1; SMN2RAB9ANPC1PDE4D | |
| SCHEMBL15167569 | 0.86 | ALDH1A1 (0.61) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL6314704 | 0.86 | RAB9A (0.59) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL6313469 | 0.86 | MAPT (0.63) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL6052641 | 0.85 | ALDH1A1 (0.60) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL8339357 | 0.85 | ALDH1A1 (0.60) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL5680826 | 0.85 | ALDH1A1 (0.60) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL29209983 | 0.85 | RAB9A (0.50) | MAPTSMN1; SMN2RAB9ANPC1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2657230-A1 | AMIDE DERIVATIVE AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| US-5888941-A | Carbozamides with antifungal activity | J. URIACH & CIA. S.A. (ES) | 1999-03-30 | — | — | US | disclosed |
| EP-0783502-A1 | NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997005131-A1 | NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | IL2, IL4, IL5 | MAPT 1285/4885SMN1; SMN2 3412/4885RAB9A 1528/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | MAPT 4418/4885SMN1; SMN2 3122/4885RAB9A 2117/4885 |
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | MAPT 1700/4885SMN1; SMN2 1271/4885RAB9A 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.